These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 38887386)

  • 1. Effectiveness of galcanezumab on sleep quality, migraine outcome, and multidimensional patient-reported outcome measures: a real-world experience in Turkish patients with episodic and chronic migraine.
    Ilgaz Aydinlar E; Erdogan Soyukibar T; Yalinay Dikmen P
    Front Neurol; 2024; 15():1411238. PubMed ID: 38887386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effectiveness and predictors influencing the outcome of onabotulinumtoxinA treatment in chronic migraine: understanding from diverse patient profiles in a single session.
    Ilgaz Aydinlar E; Erdogan Soyukibar T; Yalinay Dikmen P
    Front Neurol; 2024; 15():1417303. PubMed ID: 38962481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Impact of Fibromyalgia on Disability, Anxiety, Depression, Sleep Disturbance, and Quality of Life in Patients with Migraine.
    Beyazal MS; Tüfekçi A; Kırbaş S; Topaloğlu MS
    Noro Psikiyatr Ars; 2018; 55(2):140-145. PubMed ID: 30057455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study).
    Vernieri F; Altamura C; Brunelli N; Costa CM; Aurilia C; Egeo G; Fofi L; Favoni V; Pierangeli G; Lovati C; Aguggia M; d'Onofrio F; Doretti A; Di Fiore P; Finocchi C; Rao R; Bono F; Ranieri A; Albanese M; Cevoli S; Barbanti P;
    J Headache Pain; 2021 May; 22(1):35. PubMed ID: 33941080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With Migraine.
    Ford JH; Kurth T; Starling AJ; Ayer DW; Wietecha LA; Port MD; Rettiganti M; Ruff DD
    Headache; 2020 Nov; 60(10):2304-2319. PubMed ID: 33249580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Galcanezumab effect on "whole pain burden" and multidimensional outcomes in migraine patients with previous unsuccessful treatments: a real-world experience.
    Silvestro M; Tessitore A; Orologio I; De Micco R; Tartaglione L; Trojsi F; Tedeschi G; Russo A
    J Headache Pain; 2022 Jun; 23(1):69. PubMed ID: 35698070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials).
    Ailani J; Andrews JS; Rettiganti M; Nicholson RA
    J Headache Pain; 2020 Oct; 21(1):123. PubMed ID: 33069214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cervical non-invasive vagus nerve stimulation (nVNS) for preventive and acute treatment of episodic and chronic migraine and migraine-associated sleep disturbance: a prospective observational cohort study.
    Kinfe TM; Pintea B; Muhammad S; Zaremba S; Roeske S; Simon BJ; Vatter H
    J Headache Pain; 2015; 16():101. PubMed ID: 26631234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2).
    Silberstein SD; Stauffer VL; Day KA; Lipsius S; Wilson MC
    J Headache Pain; 2019 Jun; 20(1):75. PubMed ID: 31253091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Galcanezumab for Migraine Prevention in Patients With a Medical History of Anxiety and/or Depression: A Post Hoc Analysis of the Phase 3, Randomized, Double-Blind, Placebo-Controlled REGAIN, and Pooled EVOLVE-1 and EVOLVE-2 Studies.
    Smitherman TA; Tietjen GE; Schuh K; Skljarevski V; Lipsius S; D'Souza DN; Pearlman EM
    Headache; 2020 Nov; 60(10):2202-2219. PubMed ID: 33063862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Shift from high-frequency to low-frequency episodic migraine in patients treated with Galcanezumab: results from two global randomized clinical trials.
    Jedynak J; Eross E; Gendolla A; Rettiganti M; Stauffer VL
    J Headache Pain; 2021 May; 22(1):48. PubMed ID: 34049484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of greater occipital nerve blockade on the quality of life, disability and comorbid depression, anxiety, and sleep disturbance in patients with chronic migraine.
    Ulusoy EK; Bolattürk ÖF
    Neurol Sci; 2020 Jul; 41(7):1829-1835. PubMed ID: 32056056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional impairment and disability among patients with migraine: evaluation of galcanezumab in a long-term, open-label study.
    Ford JH; Stauffer VL; McAllister P; Akkala S; Sexson M; Ayer DW; Wang S
    Qual Life Res; 2021 Feb; 30(2):455-464. PubMed ID: 32944843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Migraine Disability Improvement during Treatment with Galcanezumab in Patients with Chronic and High Frequency Episodic Migraine.
    di Cola FS; Bolchini M; Caratozzolo S; Ceccardi G; Cortinovis M; Liberini P; Rao R; Padovani A
    Neurol Int; 2023 Feb; 15(1):273-284. PubMed ID: 36810472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measures of Functioning in Patients With Episodic Migraine: Findings From a Double-Blind, Randomized, Placebo-Controlled Phase 2b Trial With Galcanezumab.
    Ayer DW; Skljarevski V; Ford JH; Nyhuis AW; Lipton RB; Aurora SK
    Headache; 2018 Sep; 58(8):1225-1235. PubMed ID: 30106172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two randomized migraine studies of galcanezumab: Effects on patient functioning and disability.
    Ford JH; Ayer DW; Zhang Q; Carter JN; Leroux E; Skljarevski V; Aurora SK; Tockhorn-Heidenreich A; Lipton RB
    Neurology; 2019 Jul; 93(5):e508-e517. PubMed ID: 31270220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Annual indirect costs savings in patients with episodic or chronic migraine: a post-hoc analysis of phase 3 galcanezumab clinical trials in the United States.
    Varnado OJ; Ye W; Mi X; Burge R; Hall J
    J Med Econ; 2023; 26(1):149-157. PubMed ID: 36601798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Analysis of the EVOLVE Studies.
    Detke HC; Millen BA; Zhang Q; Samaan K; Ailani J; Dodick DW; Aurora SK
    Headache; 2020 Feb; 60(2):348-359. PubMed ID: 31710104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study.
    Hu B; Li G; Li X; Wu S; Yu T; Li X; Zhao H; Jia Z; Zhuang J; Yu S
    J Headache Pain; 2022 Jul; 23(1):90. PubMed ID: 35896988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial.
    Stauffer VL; Dodick DW; Zhang Q; Carter JN; Ailani J; Conley RR
    JAMA Neurol; 2018 Sep; 75(9):1080-1088. PubMed ID: 29813147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.